Protalix BioTherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLX research report →
Companywww.protalix.com
Protalix BioTherapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease.
- CEO
- Dror Bashan
- IPO
- 1998
- Employees
- 213
- HQ
- Hackensack, NJ, US
Price Chart
Valuation
- Market Cap
- $161.95M
- P/E
- 10.47
- P/S
- 2.12
- P/B
- 2.39
- EV/EBITDA
- 6.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.97%
- Op Margin
- 25.91%
- Net Margin
- 20.07%
- ROE
- 28.10%
- ROIC
- 20.62%
Growth & Income
- Revenue
- $52.74M · -1.23%
- Net Income
- $-6,604,000 · -325.24%
- EPS
- $-0.08 · -308.17%
- Op Income
- $-5,500,000
- FCF YoY
- -284.40%
Performance & Tape
- 52W High
- $3.19
- 52W Low
- $1.32
- 50D MA
- $2.22
- 200D MA
- $2.12
- Beta
- -0.01
- Avg Volume
- 956.30K
Get TickerSpark's AI analysis on PLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 24, 25 | Mamlok Gilad | other | 0 |
| Dec 19, 25 | Bashan Dror | buy | 56,000 |
| Nov 18, 25 | Bar-Shalev Amos | sell | 168 |
| Sep 3, 25 | Melincoff Gwen A | other | 15,000 |
| Sep 3, 25 | Forster Eliot | other | 15,000 |
| Sep 3, 25 | Forster Eliot | other | 7,500 |
| Sep 3, 25 | Melincoff Gwen A | other | 7,500 |
| Sep 3, 25 | Boudes Pol F | other | 15,000 |
| Sep 3, 25 | Boudes Pol F | other | 7,500 |
| Sep 3, 25 | Elze Christian | other | 15,000 |
Our PLX Coverage
We haven't published any research on PLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PLX Report →